Literature DB >> 22614900

T-cell subset distribution in HIV-1-infected patients after 12 years of treatment-induced viremic suppression.

Frederikke F Rönsholt1, Henrik Ullum, Terese L Katzenstein, Jan Gerstoft, Sisse R Ostrowski.   

Abstract

OBJECTIVE: Residual immune activation and skewed T cell maturation may contribute to excess comorbidity and mortality in successfully treated HIV-infected patients, and long-term effects of combination antiretroviral therapy (cART) on immune reconstitution remain a debated issue. Quantitative T cell reconstitution and activation and its association with residual viremia in patients with 12 years of viremic suppression were investigated.
DESIGN: Blood samples collected cross-sectionally from 71 HIV-infected patients with cART-induced viremic suppression through 12 years were compared with samples from 16 healthy controls.
METHODS: Several different subsets of naive, memory, and activated T cells were analyzed in fresh whole blood by 6-color flowcytometry, and ultrasensitive quantification of HIV RNA was performed.
RESULTS: HIV-infected patients had lower absolute and relative CD4 T cell counts and higher absolute and relative CD8 T cell counts than controls. HIV-infected patients had lower concentrations of naive CD4 cells than controls, but proportions were similar. HIV-infected patients had higher concentrations of CD8 T cells than controls in all the examined subsets but only a higher proportion of CD8 cells in the intermediately differentiated and activated subsets. Residual viremia did not correlate to proportions of naive CD4, CD4 recent thymic emigrants, or activated CD8 T cells.
CONCLUSIONS: This study demonstrated some degree of T cell imbalance even after 12 years of successful cART. Large longitudinal studies are needed to establish whether these discrete changes have clinical relevance.

Entities:  

Mesh:

Year:  2012        PMID: 22614900     DOI: 10.1097/QAI.0b013e31825e7ac1

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  13 in total

1.  HIV-1 and the immune response to TB.

Authors:  Naomi F Walker; Graeme Meintjes; Robert J Wilkinson
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

2.  Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.

Authors:  Bret J Rudy; Bill G Kapogiannis; Carol Worrell; Kathleen Squires; James Bethel; Su Li; Craig M Wilson; Allison Agwu; Patricia Emmanuel; Georgine Price; Stephanie Hudey; Maureen M Goodenow; John W Sleasman
Journal:  J Acquir Immune Defic Syndr       Date:  2015-05-01       Impact factor: 3.731

3.  Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.

Authors:  Allan R Tenorio; Yu Zheng; Ronald J Bosch; Supriya Krishnan; Benigno Rodriguez; Peter W Hunt; Jill Plants; Arjun Seth; Cara C Wilson; Steven G Deeks; Michael M Lederman; Alan L Landay
Journal:  J Infect Dis       Date:  2014-05-01       Impact factor: 5.226

4.  Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.

Authors:  Meagan O'Brien; Emilie Montenont; Liang Hu; Michael A Nardi; Vanessa Valdes; Michael Merolla; Gabrielle Gettenberg; Karen Cavanagh; Judith A Aberg; Nina Bhardwaj; Jeffrey S Berger
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07-01       Impact factor: 3.731

5.  Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts.

Authors:  Wei Cao; Vikram Mehraj; Benoit Trottier; Jean-Guy Baril; Roger Leblanc; Bertrand Lebouche; Joseph Cox; Cecile Tremblay; Wei Lu; Joel Singer; Taisheng Li; Jean-Pierre Routy; S Vézina; L Charest; M Milne; E Huchet; S Lavoie; J Friedman; M Duchastel; F Villielm; P Côté; M Potter; B Lessard; M A Charron; S Dufresne; M E Turgeon; D Rouleau; L Labrecque; C Fortin; A de Pokomandy; V Hal-Gagné; M Munoz; B Deligne; V Martel-Laferrière; N Gilmore; M Fletcher; J Szabo
Journal:  Clin Infect Dis       Date:  2015-09-08       Impact factor: 9.079

6.  Thromboelastography on plasma reveals delayed clot formation and accelerated clot lyses in HIV-1 infected persons compared with healthy controls.

Authors:  Frederikke Falkencrone Rönsholt; Jan Gerstoft; Henrik Ullum; Pär Ingemar Johansson; Terese Lea Katzenstein; Sisse Rye Ostrowski
Journal:  BMC Infect Dis       Date:  2015-09-24       Impact factor: 3.090

7.  Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort Study.

Authors:  F De Salvador-Guillouët; C Sakarovitch; J Durant; K Risso; E Demonchy; P M Roger; E Fontas
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

8.  Baseline Naive CD4+ T-cell Level Predicting Immune Reconstitution in Treated HIV-infected Late Presenters.

Authors:  Fu-Ping Guo; Yi-Jia Li; Zhi-Feng Qiu; Wei Lv; Yang Han; Jing Xie; Yan-Ling Li; Xiao-Jing Song; Shan-Shan Du; Vikram Mehraj; Tai-Sheng Li; Jean-Pierre Routy
Journal:  Chin Med J (Engl)       Date:  2016-11-20       Impact factor: 2.628

Review 9.  Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era.

Authors:  Wei Cao; Vikram Mehraj; Daniel E Kaufmann; Taisheng Li; Jean-Pierre Routy
Journal:  J Int AIDS Soc       Date:  2016-03-03       Impact factor: 5.396

10.  Reduction in terminally differentiated T cells in virologically controlled HIV-infected aging patients on long-term antiretroviral therapy.

Authors:  Nicole E Behrens; Anne Wertheimer; Stephen A Klotz; Nafees Ahmad
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.